CICCHIELLO, FEDERICA
CICCHIELLO, FEDERICA
Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study
2019 Cazzaniga, M; Pinotti, G; Montagna, E; Amoroso, D; Berardi, R; Butera, A; Cagossi, K; Cavanna, L; Ciccarese, M; Cinieri, S; Cretella, E; De Conciliis, E; Febbraro, A; Ferrau, F; Ferzi, A; Fiorentini, G; Fontana, A; Gambaro, A; Garrone, O; Gebbia, V; Generali, D; Gianni, L; Giovanardi, F; Grassadonia, A; Leonardi, V; Marchetti, P; Melegari, E; Musolino, A; Nicolini, M; Putzu, C; Riccardi, F; Santini, D; Saracchini, S; Sarobba, M; Schintu, M; Scognamiglio, G; Spadaro, P; Taverniti, C; Toniolo, D; Tralongo, P; Turletti, A; Valenza, R; Valerio, M; Vici, P; Clivio, L; Torri, V; Cicchiello, F; Riva, F; Vallini, I; Mazza, M; Bonfadini, C; Bordin, E; Canicatti, M; Cappuccio, F; Collova, E; De Angelis, C; Desorte, R; Donati, S; Drudi, G; Galanti, D; Mocerino, C; Orlando, L; Pellegrino, B; Pizzuti, L; Ridolfi, C; Rocca, A; Sarti, D; Spagnoletti, I; Tinari, N; Vandone, A; Vizzini, L
A possible biomarker for paclitaxel-induced peripheral neurotoxicity: Neurofilament light chain serum levels monitoring
2020 Alberti, P; Cicchiello, F; Riva, F; Cavaletti, G; Cazzaniga, M
Neurofilament light chain serum levels as a possible paclitaxel-induced peripheral neurotoxicity biomarker: pilot and feasibility study.
2020 Alberti, P; Cicchiello, F; Riva, F; Cazzaniga, M
Comparison of tumor microenvironment in primary and paired metastatic ER+/HER2- breast cancers: results of a pilot study
2021 Zeppellini, A; Galimberti, S; Leone, B; Pacifico, C; Riva, F; Cicchiello, F; Capici, S; Maggioni, C; Sala, L; Cazzaniga, M
Validation of the Italian version of the full and abbreviated Trust in Oncologist Scale
2021 Bani, M; Rossi, E; Cortinovis, D; Russo, S; Gallina, F; Hillen, M; Canova, S; Cicchiello, F; Longarini, R; Cazzaniga, M; Bidoli, P; Valsecchi, M; Strepparava, M
Immunomodulatory effects of metronomic vinorelbine (mVRL), with or without metronomic capecitabine (mCAPE), in hormone receptor positive (HR+)/HER2-negative metastatic breast cancer (MBC) patients: final results of the exploratory phase 2 Victor-5 study
2022 Pepe, F; Cazzaniga, M; Baroni, S; Riva, F; Cicchiello, F; Capici, S; Cogliati, V; Maggioni, C; Cordani, N; Cerrito, M; Malandrin, S
How to Treat HR+/HER2-Metastatic Breast Cancer Patients after CDK4/6 Inhibitors: An Unfinished Story
2022 Cogliati, V; Capici, S; Pepe, F; Di Mauro, P; Riva, F; Cicchiello, F; Maggioni, C; Cordani, N; Cerrito, M; Cazzaniga, M
Baseline 18FDG-PET Metabolic Tumour Volume (MTV) as a Potential Predictive Factor of Response to Metronomic Chemotherapy (mCHT) in HR+/HER2- Metastatic Breast Cancer (MBC) Patients (pts). Preliminary Results of the Metro-pet Study
2023 Meazza Prina, M; Gotuzzo, I; Cazzaniga, M; De Bernardi, E; Cafaro, P; Capici, S; Cogliati, V; Fulvia Pepe, F; Cicchiello, F; Riva, F; Cordani, N; Cerrito, M; Turolla, E; Landoni, C; Elisei, F; Crivellaro, C; Virdone, L; Monaco, L; Guidi, A; Guerra, L